Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Schlumberger NV — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Schlumberger NV trades at $48.73 (market cap $72.38B). The key difference: Schlumberger NV is far larger — about 74.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Schlumberger NV pays a 2.42% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| MRVI | SLB | |
|---|---|---|
Market Cap | $972.90M | $72.38B |
Volume | 4,325,710 | 10,231,115 |
Sector | Health | Energy |
52-Week High | $9.00 | $60.10 |
52-Week Low | $2.83 | $32.57 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $1.08B | $81.11B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SLB trades at $48.51, down 0.53% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with 8.53% net income margin and 13.37% ROE, though revenue declined slightly to $35.71B in 2025. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility. Analyst consensus remains strongly bullish with 85% buy ratings and $64.58 price target representing 33% upside potential.
SLB presents a compelling value opportunity with solid fundamentals and strong analyst support, though near-term headwinds include declining profit margins and bearish technical indicators. The company's recent major contract awards and dividend payments provide stability, but investors should monitor execution risks in international markets and potential volatility in energy sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
